<DOC>
	<DOCNO>NCT01134718</DOCNO>
	<brief_summary>The purpose study compare healthy volunteer level TMC435 blood circulation intake 2 new capsule formulation level TMC435 blood circulation intake capsule formulation use Phase IIb study .</brief_summary>
	<brief_title>TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations TMC435 Established Capsule Formulation Evaluating Respective Blood Levels TMC435 Following Single Dose Administration</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , open-label ( people involve know treatment ) , single dose , crossover ( volunteer receive different treatment sequentially trial ) study healthy volunteer . The trial evaluate level TMC435 blood circulation single dose 150 mg TMC435 administer 3 different capsule formulation follow breakfast . There 7-day washout period treatment 4-5 week follow-up end . Each volunteer receive three treatment . The main focus trial pharmacokinetic characteristic ( drug absorb body , distribute within body remove body time ) different formulation . This evaluation require multiple blood sample Day 1 72 hour dose . Safety assessment ( lab work , blood pressure , pulse electrocardiogram ) follow different schedule measure Day -1 ( day prior take first dose drug ) , Day 1 ( without lab work ) Day 4 treatment period , 1 4-5 week last treatment . Each volunteer receive 3 treatment , 7 day apart . Each treatment consist one single oral dose 150 mg TMC435 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Nonsmoker least 3 month Body Mass Index 18.0 30.0 kg/m2 Healthy base medical evaluation include medical history , physical examination , blood test electrocardiogram Infection Hepatitis A , B C virus Infection human immunodeficiency virus ( HIV ) History , current medical condition could impact safety participant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>TMC435-TiDP16-C119</keyword>
	<keyword>TMC435-C119</keyword>
	<keyword>TMC435</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Bioavailability</keyword>
</DOC>